Endocrinology, diabetes and metabolic diseases

Study Drug: A drug from the PCSK9 inhibitor group, already registered for treating elevated lipids. It is available to patients who have had a myocardial infarction and, with existing medications, have excessively high LDL cholesterol. In the context of this study, the drug can be given to patients who have not had a myocardial infarction but are at a high risk of it.

Study Drug: Experimental drug “transfers” cholesterol from bad particles (LDL) to good particles (HDL) of cholesterol.